卡瑞利珠单抗联合肝动脉化疗栓塞术治疗中晚期原发性肝癌患者的效果

Effects of Reslizumab combined with transcatheter arterial chemoembolization in treatment of patients with middle and advanced primary liver cancer

目的:观察卡瑞利珠单抗联合肝动脉化疗栓塞术(TACE)治疗中晚期原发性肝癌患者的效果。方法:选取2020-2022年该院收治的70例中晚期原发性肝癌患者进行前瞻性研究,采用随机数字表法将其分为对照组和观察组各35例。对照组给予TACE治疗,观察组在对照组基础上联合卡瑞利珠单抗治疗,比较两组临床疗效,治疗前后血清学指标[天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)]、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)、甲胎蛋白异质体L3(AFP-L3)]水平,以及不良反应/并发症发生率。结果:观察组疾病控制率为94.29%(33/35),高于对照组的77.14%(27/35),差异有统计学意义(P<0.05);两组客观缓解率比较,差异无统计学意义(P>0.05);治疗后,观察组AST、ALT、TBIL水平均低于对照组,ALB水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组AFP、CEA、AFP-L3水平均低于对照组,差异有统计学意义(P<0.05);观察组不良反应/并发症发生率为48.71%(17/35),高于对照组的25.71%(9/35),差异有统计学意义(P<0.05)。结论:卡瑞利珠单抗联合TACE治疗中晚期原发性肝癌患者可提高疾病控制率,改善血清学指标水平,降低肿瘤标志物水平,效果优于单纯TACE治疗,但会增高不良反应/并发症发生率。

Objective:To observe effects of Reslizumab combined with transcatheter arterial chemoembolization(TACE)in treatment of patients with middle and advanced primary liver cancer.Methods:A prospective study was conducted on 70 patients with middle and advanced primary liver cancer admitted to this hospital from 2020 to 2022.They were divided into control group and observation group by using the random number table method,35 cases in each group.The control group was treated with TACE,while the observation group was treated with Reslizumab on the basis of that of the control group.The clinical efficacy,the levels of serological indexes[aspartate aminotransferase(AST),alanine aminotransferase(ALT),albumin(ALB),total bilirubin(TBIL)]and the tumor markers[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),alpha-fetoprotein heterogeneity L3(AFP-L3)]before and after the treatment,and the incidence of adverse reactions/complications were compared between the two groups.Results:The disease control rate of the observation group was 94.29%(33/35),which was higher than 77.14%(27/35)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of AST,ALT and TBIL in the observation group were lower than those in the control group,the level of ALB was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of AFP,CEA and AFP-L3 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions/complications in the observation group was 48.71%(17/35),which was higher than 25.71%(9/35)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Reslizumab combined with TACE in the treatment of the patients with middle and advanced primary liver cancer can improve the disease control rate,improve the levels of serological indexes,and reduce the levels of tumor markers.Moreover,it is superior to single TACE treatment,but it will increase the incidence of adverse reactions/complications.